A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
Sponsor: Sage Therapeutics
Terminated
Internal company decision
Other terminated trials from Sage Therapeutics
More terminations from Sage Therapeutics
Other Acute Respiratory Distress Syndrome trials with similar outcome
This PHASE3 trial investigates Acute Respiratory Distress Syndrome and COVID-19 and is currently terminated or withdrawn. Sage Therapeutics leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Feb 2022 — Sep 2022 [monthly]
Terminated PHASE3
-
Sep 2021 — Feb 2022 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 6 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sage Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .